[Genotypic resistance of human immunodeficiency virus type 1 in patients with therapeutic failure].
OBJECTIVE
The aim of the present study is to analyse both the frequency of resistances to the different antiretrovirals and the implication of the mayor associated resistance mutations in a group of patients with therapeutic failure.


METHODS
He sequence of protease (pr) and retrotranscriptase (rt) of HIV-1 isolated from blood were analysed in 284 patients. The viral load level was between 500 and 106 copies/ml. The genotype was made with TRUGENETM HIV-1 kit, which is based in the synthesis of cDNA by RT-PCR and sequenciation of this cDNA by PCR.


RESULTS
39,78% of the patients have not associated resistance mutations in the antiretrovirales used in the treatment, including 73 patients who have not associated resistance mutations to antiretrovirales. 60,2% of the patients have associated resistance mutations in the antiretrovirales used in the treatment. In the patients multitreated, 88,2% presented resistance to some and 53% presented genotypic resistance or possible resistance to some of the TARGA treatment.


CONCLUSIONS
The prevalence of resistance mutations in patients with therapeutic failure is bigger than 50% with both genes.
Departamento de Microbiología. Facultad de Medicina. Universidad de Sevilla. Sevilla. Spain. jmrodriguez@us.es
José Manuel
JM
Rodríguez Martínez
José Carlos
JC
Palomares Folia
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018076:DNA, Complementary / Q000032:analysis; D024882:Drug Resistance, Viral / Q000235:genetics*; D005787:Gene Frequency; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D015995:Prevalence; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013030:Spain / Q000453:epidemiology; D017211:Treatment Failure; D019562:Viral Load; D014764:Viral Proteins / Q000032:analysis / Q000235:genetics
D044966:Anti-Retroviral Agents; D018076:DNA, Complementary; D014764:Viral Proteins